Fig. 5: Matched metCRC PDOs exhibit differential sensitivity patterns to QPOP-optimised drug combinations. | npj Precision Oncology

Fig. 5: Matched metCRC PDOs exhibit differential sensitivity patterns to QPOP-optimised drug combinations.

From: A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Fig. 5

a Representative polygonograms depicting the effects of all two-drug combinations between 5-fluorouracil (5-FU), oxaliplatin (OXA), leucovorin (LEU), SN-38 (SN38), regorafenib (REG), pemrametostat (PEM), TP-064 (TP064), decitabine (DEC), entinostat (ENT) and vorinostat (VOR) in matched metCRC PDOs (n = 2; Supplementary Fig. 6). The coloured lines represent the ranked percentile of the geometric means for the viabilities of the PDOs in response to each combination. (Red, most effective, 75–100th percentile; pink and dotted, second most effective, 50–75th percentile; light blue and dotted, second least effective, 25–50th percentile; dark blue, least effective, 0–25th percentile). b Representative parabolic response surface maps illustrating the projected efficacy of the QPOP-optimised drug pairs on organoid viability for each respective pair of matched metCRC PDOs (n = 2; Supplementary Fig. 6).

Back to article page